The early-stage biotech investment landscape has undergone substantial changes in recent years. From the buoyant investment period during the pandemic to the current stabilization at pre-pandemic levels, the sector faces a mix of challenges and evolving strategies. One of the most significant
The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and
In recent years, the biotech sector has faced significant challenges in the initial public offering (IPO) market. The economic downturn and financial uncertainties have created a tough environment for companies looking to go public. However, some biotech firms, such as Bicara Therapeutics and Zenas
In an era where sustainability is no longer an option but a necessity, the pharmaceutical industry finds itself grappling with significant challenges in its commitment to sustainable practices. A recent survey by Cytiva and FT Longitude paints a complex picture of the industry’s sustainability
Sustainability has become a paramount concern in the biopharma industry, as evidenced by a recent comprehensive survey conducted by Cytiva and the Financial Times research unit, FT Longitude. This survey, involving over 800 executives from diverse global companies, reveals a growing commitment to
Employee turnover in the biopharma industry has reached unprecedented levels in recent years, causing a significant threat to intellectual property (IP) security. As the sector grapples with layoffs and recruitment shifts, there is an increasing need to understand how these workforce changes impact
